Introduction — a Canadian wake-up call
Shocking but clear: diabetes affects millions of Canadians and its burden is growing. National surveillance and health‑system analyses show rising prevalence, rising drug expenditure, and persistent inequities in outcomes—especially lower limb complications—making the 2026 Diabetes Canada guideline updates immediately relevant to patients, clinicians and policy-makers. ([cihi.ca](https://www.cihi.ca/sites/default/files/document/pan-canadian-primary-health-care-indicator-update-report-en.pdf?utm_source=openai))
What the 2026 update changes — the headlines
Diabetes Canada’s Clinical Practice Guidelines (CPG) are continuously updated; the 2026 materials consolidate recent pharmacologic and technology evidence and put emphasis on:
- firm diagnostic thresholds in mmol/L and A1C with guidance on confirmatory testing for asymptomatic individuals. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter3?utm_source=openai))
- individualised glycaemic targets (A1C and pre/post‑prandial glucose ranges) based on age, comorbidity and hypoglycaemia risk. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter41?utm_source=openai))
- evidence-based use of GLP‑1 RAs and SGLT2 inhibitors for cardiorenal risk reduction in selected patients, alongside pragmatic guidance about cost and coverage. ([jacc.org](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027?utm_source=openai))
- integration of real‑time continuous glucose monitoring (rtCGM) into care for insulin-treated patients and for targeted use in other groups where evidence supports benefits. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006558/?utm_source=openai))
Diagnosis in practical terms (mmol/L and A1C)
Per Diabetes Canada, diagnosis of diabetes in adults is established by any one of the following using standardised assays: fasting plasma glucose (FPG) ≥7.0 mmol/L; A1C ≥6.5% (except in situations where A1C is unreliable); 2‑hour plasma glucose (75 g OGTT) ≥11.1 mmol/L; or a random plasma glucose ≥11.1 mmol/L with symptoms. In asymptomatic people, a second confirmatory test on another day is recommended. These thresholds remain central to the 2026 guidance. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter3?utm_source=openai))
Who should be screened and how often?
Diabetes Canada recommends targeted screening for people with risk factors (overweight/obesity, family history, history of gestational diabetes, certain high‑risk ethnic groups, hypertension). Screening tests commonly used are fasting plasma glucose and A1C; OGTT is reserved for specific scenarios (e.g., borderline results, pregnancy planning). Regular follow-up intervals are individualised based on risk. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4?utm_source=openai))
Glycaemic targets: individualise, don’t generalise
For many non‑pregnant adults, an A1C target <7.0% remains reasonable. Diabetes Canada emphasises tailoring goals: lower targets may be appropriate for some if achievable without hypoglycaemia; higher targets may be safer in older, frail individuals or those with limited life expectancy. Preprandial glucose targets around 4–7 mmol/L are commonly cited for people able to achieve them safely; postprandial targets are likewise tailored. Discuss targets with your care team. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter41?utm_source=openai))
Pharmacologic management: GLP‑1 and SGLT2 in context
Large systematic reviews and meta‑analyses published recently show that GLP‑1 receptor agonists reduce major adverse cardiovascular events (MACE) and confer renal benefits in selected populations with T2D, while SGLT2 inhibitors provide robust evidence for heart failure and kidney protection. Diabetes Canada’s 2026 guidance recommends choosing glucose‑lowering agents that align with an individual’s cardiovascular and renal profile, balancing benefit against access and cost. In Canada this is particularly relevant because public drug spending has risen notably due to these novel agents, affecting formulary decisions. ([jacc.org](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027?utm_source=openai))
Technology: Where CGM fits
Real‑time CGM (rtCGM) and intermittently scanned CGM have strong evidence in type 1 diabetes and growing data in insulin‑treated type 2 diabetes to lower A1C and increase Time in Range (TIR). Randomised trials and pragmatic studies have shown clinically meaningful improvements when CGM is used along with education and treatment adjustment. Diabetes Canada recommends CGM for many insulin‑using people, while noting provincial variation in funding and access. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006558/?utm_source=openai))
Prevention and lifestyle — the continued foundation
Behavioural interventions remain primary prevention tools: structured programs that combine modest weight loss with ≥150 minutes of moderate‑intensity activity per week reduce progression from prediabetes to diabetes. These recommendations align with Health Canada’s Canada’s Food Guide and Healthy Eating Strategy. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter27?utm_source=openai))
Canadian data you must know
CIHI reports and national surveillance indicate increasing prevalence of diabetes and large interprovincial differences in complications such as lower limb amputations—over 3,000 amputations annually are associated with diabetes—and substantial hospitalization costs. Statistics Canada and CHMS analyses show prevalence increases over recent cycles and notable differences across ethnocultural groups and age strata. These national data underpin the equity focus in the 2026 guidance. ([cihi.ca](https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation/amputations-signal-opportunities-to-improve-diabetes-care-and-reduce-system-costs?utm_source=openai))
What this means for care in each province
Practical implementation depends on provincial systems: primary care remains the entry point in most regions, but access to endocrinology, diabetes education, CGM funding and certain drug formularies vary between Ontario, BC, Alberta and Quebec. Check provincial program pages or Diabetes Canada resources for local guidance and coverage details. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html?utm_source=openai))
How to act on the guidelines — a short checklist
- Know your numbers: ask for A1C and fasting plasma glucose (in mmol/L). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter3?utm_source=openai))
- Discuss personalised A1C and glucose targets with your provider. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter41?utm_source=openai))
- Ask about cardiorenal‑protective drugs if you have heart or kidney disease, and discuss funding options. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39210781/?utm_source=openai))
- If insulin-treated, discuss CGM and whether provincial funding is an option. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006558/?utm_source=openai))
- Engage in structured lifestyle programmes and use Canada’s Food Guide to plan meals. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter27?utm_source=openai))
Evidence behind major recommendations (select international studies)
Recent systematic reviews and RCTs (2021–2025) shaped the 2026 recommendations: large meta‑analyses on GLP‑1 RAs and cardiovascular outcomes, network meta‑analyses comparing GLP‑1 agents, and multiple trials and real‑world studies on CGM effectiveness informed the pharmacologic and technology sections. Examples include major PubMed‑indexed meta‑analyses and JACC analyses summarising CV/renal benefits. ([jacc.org](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027?utm_source=openai))
How Feel Great connects to Diabetes Canada 2026 (cautious, evidence‑aware perspective)
Feel Great is presented as a lifestyle support system (not a medication). Components described by the system — a soluble fibre matrix (Balance) designed to blunt post‑meal glycaemic excursions, Unimate (yerba mate extract) for energy and mental focus, and lifestyle protocols such as the 4‑4‑12 intermittent fasting schedule — can complement the non‑pharmacologic pieces of Diabetes Canada’s guidance, especially in weight management, meal planning and adherence to behaviour change. Such products and routines may help individuals adopt guideline‑recommended habits but must be used within a clinical plan and with professional oversight. Always check product labelling for Health Canada NPNs where applicable and discuss with your clinician.
People Also Ask
- What changed in Diabetes Canada Guidelines 2026? — Emphasis on individualised targets, integration of newer pharmacologic evidence and clearer guidance on CGM use and access. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/home?utm_source=openai))
- Are the diagnostic cut‑offs different? — No, the core diagnostic thresholds remain (A1C ≥6.5%; FPG ≥7.0 mmol/L; 2h OGTT ≥11.1 mmol/L). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter3?utm_source=openai))
- Should all insulin users have CGM? — Many will benefit; Diabetes Canada supports CGM for insulin-dependent patients while noting funding varies by province. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006558/?utm_source=openai))
- Do GLP‑1s reduce heart attack or stroke? — Meta‑analyses show reductions in MACE for selected GLP‑1 RAs in patients with T2D, but therapy should be individualised. ([jacc.org](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027?utm_source=openai))
- How do I find local diabetes education? — Diabetes Canada and provincial diabetes programs list DSMES and local clinics; ask your primary care team. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/home?utm_source=openai))
FAQ (short answers)
- Does the guideline tell me to stop medications if I lose weight?
No—any medication changes must be guided by your care team with monitored labs and follow‑up. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter41?utm_source=openai)) - Is CGM funded across Canada?
No—coverage is provincial and varies by age, indication and program. Check with provincial programs. ([canadacgm.com](https://www.canadacgm.com/wp-content/uploads/2024/06/Coverage-Infographic-June-24-v2.pdf?utm_source=openai)) - Should everyone with prediabetes be started on medication?
Not routinely—behavioural interventions are first‑line; medication may be considered in selected high‑risk cases. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter27?utm_source=openai)) - How often should A1C be checked?
Usually every 3 months until stable and then every 3–6 months based on control and therapy changes. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter41?utm_source=openai)) - Where can I read the full guidelines?
Diabetes Canada’s Clinical Practice Guidelines site hosts chapters and updates. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/home?utm_source=openai))
References & scientific sources (selected)
- Diabetes Canada — Clinical Practice Guidelines online (2024–2026 updates). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/home?utm_source=openai))
- Health Canada — Framework for Diabetes in Canada; Canada’s Food Guide. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html?utm_source=openai))
- Canadian Institute for Health Information — Equity in diabetes care: A focus on lower limb amputation (2024). ([cihi.ca](https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation?utm_source=openai))
- Statistics Canada — Diabetes prevalence and CHMS analyses. ([statcan.gc.ca](https://www.statcan.gc.ca/o1/en/plus/5103-diabetes-among-canadian-adults?utm_source=openai))
- JACC / PubMed — Systematic reviews/meta‑analyses on GLP‑1 RAs and cardiovascular outcomes (2024–2025). ([jacc.org](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027?utm_source=openai))
- Multiple RCTs and real‑world studies on CGM effectiveness and adoption. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006558/?utm_source=openai))
- Heart & Stroke Foundation — Diabetes and cardiovascular disease resources. ([heartandstroke.ca](https://www.heartandstroke.ca/-/media/pdf-files/canada/health-information-catalogue/en-diabetes-and-you-v5-4-web.ashx?utm_source=openai))
Medical disclaimer
This article is for information only and is not medical advice. Always consult your physician or diabetes care team before making changes to medication, devices, or care plans. The "Feel Great" system is presented as a lifestyle support option and is not a medication; discuss any supplements or new programmes with a licensed clinician.